Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
💡 한 문장 핵심
양성전립선비대증 치료에서 dutasteride와 finasteride의 비교: Enlarged Prostate International Comparator Study (EPICS).
무작위 임상시험
4/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
once-daily treatment with dutasteride 0
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
• A similar percentage of adverse events was experienced by patients of both treatment groups, and no new adverse events were reported in the open-label phase. [CONCLUSION] • Dutasteride and finasteride, when administered for 12 months, were similarly effective in reducing prostate volume and improving Q(max) and urinary symptoms associated with BPH in men with an enlarged prostate.
📑 코퍼스 인용 관계
· 인용됨 15
📑 인용한 논문 (6) ▾
- Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Beni… The world journal of men's health · 2025
- Comparative Effectiveness and Safety of Finasteride and Dutasteride in the Treatment of Be… Medicina (Kaunas, Lithuania) · 2025
- Suicidal risk associated with finasteride versus dutasteride among men treated for benign … Scientific reports · 2023
- The efficacy and safety of dutasteride and finasteride in patients with benign prostatic h… Translational andrology and urology · 2022
- Can we predict prostate size by scoring baldness? The relationship of androgenic alopecia … Central European journal of urology · 2019
- BCL-2 and BCL-XL expression are down-regulated in benign prostate hyperplasia nodules and … American journal of clinical and experimental urology · 2018
연도별 인용 (2012–2026) · 합계 216
OpenAlex 토픽 ·
Urinary Bladder and Prostate Research
Sexual function and dysfunction studies
Prostate Cancer Diagnosis and Treatment
Abstract 🌐 Abstract
[OBJECTIVE] • To assess the efficacy and safety of dutasteride compared with finasteride in treating men with symptomatic benign prostatic hyperplasia (BPH) for 12 months.
[PATIENTS AND METHODS] • The Enlarged Prostate International Comparator Study was a multicentre, randomized, double-blind, 12-month, parallel-group study. • Men aged ≥ 50 years with a clinical diagnosis of BPH received once-daily treatment with dutasteride 0.5 mg (n= 813) or finasteride 5 mg (n= 817). After a 4-week placebo run-in period, patients were randomized to receive dutasteride or finasteride for 48 weeks, followed by an optional 24-month, open-label phase, during which patients received dutasteride 0.5 mg once daily. • The primary endpoint was change in prostate volume, and the secondary endpoints included improvement in American Urological Association Symptom Index (AUA-SI) scores, improvement in maximum urinary flow rate (Q(max)) and long-term safety in the 24-month open-label phase.
[RESULTS] • Both dutasteride and finasteride were effective at reducing prostate volume with no significant difference between the two treatments during the study. • Similar reductions in mean AUA-SI scores and Q(max) were also observed for men in both treatment groups. • A similar percentage of adverse events was experienced by patients of both treatment groups, and no new adverse events were reported in the open-label phase.
[CONCLUSION] • Dutasteride and finasteride, when administered for 12 months, were similarly effective in reducing prostate volume and improving Q(max) and urinary symptoms associated with BPH in men with an enlarged prostate.
[PATIENTS AND METHODS] • The Enlarged Prostate International Comparator Study was a multicentre, randomized, double-blind, 12-month, parallel-group study. • Men aged ≥ 50 years with a clinical diagnosis of BPH received once-daily treatment with dutasteride 0.5 mg (n= 813) or finasteride 5 mg (n= 817). After a 4-week placebo run-in period, patients were randomized to receive dutasteride or finasteride for 48 weeks, followed by an optional 24-month, open-label phase, during which patients received dutasteride 0.5 mg once daily. • The primary endpoint was change in prostate volume, and the secondary endpoints included improvement in American Urological Association Symptom Index (AUA-SI) scores, improvement in maximum urinary flow rate (Q(max)) and long-term safety in the 24-month open-label phase.
[RESULTS] • Both dutasteride and finasteride were effective at reducing prostate volume with no significant difference between the two treatments during the study. • Similar reductions in mean AUA-SI scores and Q(max) were also observed for men in both treatment groups. • A similar percentage of adverse events was experienced by patients of both treatment groups, and no new adverse events were reported in the open-label phase.
[CONCLUSION] • Dutasteride and finasteride, when administered for 12 months, were similarly effective in reducing prostate volume and improving Q(max) and urinary symptoms associated with BPH in men with an enlarged prostate.
- 표본수 (n) 813
[OBJECTIVE] • To assess the efficacy and safety of dutasteride compared with finasteride in treating men with symptomatic benign prostatic hyperplasia (BPH) for 12 months.
APA 7
Nickel, J. C., Gilling, P., Tammela, T. L., Morrill, B., Wilson, T. H., & Rittmaster, R. S. (2011). Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: The enlarged prostate international comparator study (epics).. BJU international, 108(3), 388-94. https://doi.org/10.1111/j.1464-410X.2011.10195.x
Vancouver
Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU international. 2011;108(3):388-94. doi:10.1111/j.1464-410X.2011.10195.x
AMA 11
Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU international. 2011;108(3):388-94. doi:10.1111/j.1464-410X.2011.10195.x
Chicago
Nickel, J. C., Gilling, P., Tammela, T. L., Morrill, B., Wilson, T. H., and Rittmaster, R. S.. 2011. "Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS)." BJU international 108 (3): 388-94. https://doi.org/10.1111/j.1464-410X.2011.10195.x
MLA 9
Nickel, J. C., et al. "Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS)." BJU international, vol. 108, no. 3, 2011, pp. 388-94. doi:10.1111/j.1464-410X.2011.10195.x.
PMID
21631695 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 6/8 (75%)
· 참조 0편 · 후속 6편
이 논문을 인용한 후속 연구 15
- Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic …
- The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia…
- The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in …
- BCL-2 and BCL-XL expression are down-regulated in benign prostate hyperplasia nodules and not affect…
- Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment o…
- Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BP…
- The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate canc…
- Can we predict prostate size by scoring baldness? The relationship of androgenic alopecia and lower …
- Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness an…
- Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treate…
- Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hy…
- Comparative Effectiveness and Safety of Finasteride and Dutasteride in the Treatment of Benign Prost…
- Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostat…
- [Combined treatment of BPS with tamsulosin and finasteride : Literature review and prescription data…
- Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of …
같은 제1저자의 인용 많은 논문 (5)
- Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study.
- Comparison of clinical trials with finasteride and dutasteride.
- A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis).
- Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers.
- Placebo therapy of benign prostatic hyperplasia: a 25-month study. Canadian PROSPECT Study Group.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- 피나스테리드가 전립선암 발생에 미치는 영향.
- COVID-19의 50가지 이상의 장기 후유증: 체계적 문헌고찰 및 메타분석.
- 양성 전립선 비대증의 임상적 진행에 대한 doxazosin, finasteride 및 병용 요법의 장기 효과.
- 양성 전립선 비대증 환자에서 finasteride의 효과. The Finasteride Study Group.
- 양성 전립선 비대증 남성에서 급성 요폐의 위험과 수술적 치료 필요성에 대한 finasteride의 효과. Finasteride Long-Term Efficacy and Safety Study Group.
- 양성 전립선 비대증 남성에서 finasteride의 효과.